NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Sees Significant Increase in Short Interest

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) was the recipient of a significant increase in short interest in January. As of January 30th, there was short interest totaling 76,711 shares, an increase of 55.3% from the January 15th total of 49,408 shares. Based on an average daily volume of 273,476 shares, the short-interest ratio is currently 0.3 days. Approximately 0.2% of the company’s stock are short sold. Approximately 0.2% of the company’s stock are short sold. Based on an average daily volume of 273,476 shares, the short-interest ratio is currently 0.3 days.

Institutional Trading of NeuroOne Medical Technologies

Hedge funds and other institutional investors have recently made changes to their positions in the business. Warberg Asset Management LLC purchased a new position in NeuroOne Medical Technologies during the 2nd quarter worth $27,000. Focus Financial Network Inc. purchased a new stake in shares of NeuroOne Medical Technologies during the third quarter worth about $31,000. Legato Capital Management LLC acquired a new position in shares of NeuroOne Medical Technologies during the fourth quarter valued at about $34,000. Susquehanna International Group LLP acquired a new position in shares of NeuroOne Medical Technologies during the third quarter valued at about $47,000. Finally, XTX Topco Ltd purchased a new position in shares of NeuroOne Medical Technologies in the 2nd quarter valued at approximately $51,000. Hedge funds and other institutional investors own 16.07% of the company’s stock.

NeuroOne Medical Technologies Stock Performance

NASDAQ:NMTC opened at $0.81 on Friday. The company’s 50-day simple moving average is $0.80 and its 200-day simple moving average is $0.80. NeuroOne Medical Technologies has a fifty-two week low of $0.40 and a fifty-two week high of $1.25. The stock has a market capitalization of $41.01 million, a P/E ratio of -10.17 and a beta of 0.71.

NeuroOne Medical Technologies (NASDAQ:NMTC) last posted its quarterly earnings data on Tuesday, December 16th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.08. NeuroOne Medical Technologies had a negative net margin of 29.81% and a negative return on equity of 74.69%. The firm had revenue of $2.74 million during the quarter, compared to analyst estimates of $2.47 million. During the same quarter in the previous year, the business posted ($0.46) EPS.

Analyst Ratings Changes

Separately, Zacks Research upgraded NeuroOne Medical Technologies from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $2.23.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.